619 Results of the First-in-human Phase I Study of GDC-0068, an Akt Inhibitor That Demonstrates Safe and Sustained Targeting of the PI3K/Akt Pathway in Patients (pts) with Advanced Solid Tumors

✍ Scribed by Cervantes, A.; Saura, C.; Roda, D.; Dienstmann, R.; Rosello, S.; Carles, J.; Funke, R.; Zhu, J.; Meng, R.; Tabernero, J.

• Book ID: 123168904
• Publisher: Elsevier Science
• Year: 2012
• Tongue: English
• Weight: 58 KB
• Volume: 48
• Category: Article
• ISSN: 0959-8049
• DOI: 10.1016/S0959-8049(12)72416-4